AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22316641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 46
Study 22316641 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 46
Study 20211020 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum SP-D
Number of subjects: 160
Study 20211020 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-D during follow-up
Number of subjects: 160
Study 20211020 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-D in synovial fluid
Number of subjects: 160
Study 20211020 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SP-D
Number of subjects: 160
Study 20211020 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal changes in SP-D
Number of subjects: 160
Study 20211020 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-D
Number of subjects: 160
Study 20211020 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-D genotype
Number of subjects: 160
Study 18817809 — intervention group
Group type: EXPERIMENTAL
Intervention: P1 (intensive relaxation response training)
Number of subjects: 225
Study 18817809 — intervention group
Group type: COMPARATOR
Intervention: P2 (group program without relaxation response training)
Number of subjects: 225
Study 18817809 — intervention group
Group type: COMPARATOR
Intervention: P3 (self-guided mail-delivered program)
Number of subjects: 225
Study 16277666 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 235
Study 16277666 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 235
Study 16277666 — intervention group
Group type: EXPERIMENTAL
Intervention: Prayer
Number of subjects: 235
Study 16277666 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and cold
Number of subjects: 235
Study 16277666 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 235
Study 16277666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs
Number of subjects: 235
Study 12861112 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision lens (silicone hydrogel)
Number of subjects: 13
Study 12861112 — intervention group
Group type: COMPARATOR
Intervention: ACUVUE 2 lens (conventional hydrogel)
Number of subjects: 13
Study 10206132 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dexamethasone treatment (from day 7)
Number of subjects: 30
Study 10206132 — intervention group
Group type: COMPARATOR
Intervention: Late dexamethasone treatment (from day 14)
Number of subjects: 30
Study 7774174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental sealants combined with ongoing school-based fluoride program
Number of subjects: 416
Study 7774174 — intervention group
Group type: COMPARATOR
Intervention: Fluoride therapy only (control group)
Number of subjects: 416
Study 7774174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental sealants
Number of subjects: 416
Study 2078794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (radiation in combination with 5-FU)
Number of subjects: 0
Study 2078794 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 0
Study 78527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioctyl calcium sulfosuccinate (DCS) (Surfak), q.d.
Number of subjects: 0
Study 78527 — intervention group
Group type: COMPARATOR
Intervention: Dioctyl sodium sulfosuccinate (DSS) (Colace), q.d. and b.i.d.
Number of subjects: 0
Study 31828874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided refills
Number of subjects: 107
Study 31828874 — intervention group
Group type: COMPARATOR
Intervention: Template-guided refills
Number of subjects: 107
Study 31828874 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference after ultrasound-guided refills
Number of subjects: 107
Study 30171362 — intervention group
Group type: EXPERIMENTAL
Intervention: PFC Sigma RP‐F mobile model
Number of subjects: 110
Study 30171362 — intervention group
Group type: COMPARATOR
Intervention: PFC Sigma PS fixed model
Number of subjects: 110
Study 27502852 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7243
Study 27502852 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7243
Study 24035556 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based videoconferencing (eGetgoing)
Number of subjects: 85
Study 24035556 — intervention group
Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 85
Study 22331521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa L. aqueous extract (HSE)
Number of subjects: 8
Study 22331521 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study 20089827 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg/d for 1 week
Number of subjects: 22
Study 20089827 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 22
Study 20089827 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 22
Study 16900082 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (1-18 microg/daily)
Number of subjects: 89
Study 16900082 — intervention group
Group type: COMPARATOR
Intervention: Partly supplemented and not supplemented groups
Number of subjects: 89
Study 16900082 — intervention group
Group type: EXPERIMENTAL
Intervention: Total TC (holoTC)
Number of subjects: 89
Study 16900082 — intervention group
Group type: EXPERIMENTAL
Intervention: Total HC (holoHC)
Number of subjects: 89
Study 15338103 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (30 mg single dose)
Number of subjects: 24
Study 15338103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12017408 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 5 days
Number of subjects: 712
Study 12017408 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 7 days
Number of subjects: 712
Study 12017408 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 712
Study 12017408 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 712
Study 10850384 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus Interferon (CIFN), 9 microg, subcutaneous injection, three times weekly for 24 weeks
Number of subjects: 472
Study 10850384 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b (IFN alfa‐2b), 3 MU, subcutaneous injection, three times weekly for 24 weeks
Number of subjects: 472
Study 10850384 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype or genotype 2 or 3 (independently of treatment)
Number of subjects: 472
Study 8565197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate ophthalmic solution (0.1%)
Number of subjects: 43
Study 8565197 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 43
Study 1781800 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac plus sucralfate
Number of subjects: 24
Study 1781800 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac alone
Number of subjects: 24
Study 1781800 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam plus sucralfate
Number of subjects: 24
Study 1781800 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam alone
Number of subjects: 24
Study 7020900 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methyldopa (750 mg/d orally)
Number of subjects: 24
Study 7020900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alpha-methyldopa and chlorothiazide
Number of subjects: 24
Study 7020900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31549793 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept plus MTX
Number of subjects: 225
Study 31549793 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 225
Study 31690312 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentopexy with Glubran®2
Number of subjects: 186
Study 31690312 — intervention group
Group type: COMPARATOR
Intervention: Control group (no omentopexy with Glubran®2)
Number of subjects: 186
Study 28248896 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 60
Study 28248896 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 25060413 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 176
Study 25060413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 22544511 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin cancer education video in American Sign Language (n=75)
Number of subjects: 136
Study 22544511 — intervention group
Group type: COMPARATOR
Intervention: Alternate video (n=61)
Number of subjects: 136
Study 22544511 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (original control group)
Number of subjects: 136
Study 19533165 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CITAL 2 x 10 mg)
Number of subjects: 11
Study 19533165 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA: lactose 2 x 10 mg)
Number of subjects: 11
Study 17207172 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF (10 microg/g) in 0.1% silver sulfadiazine cream
Number of subjects: 20
Study 17207172 — intervention group
Group type: COMPARATOR
Intervention: 0.1% silver sulfadiazine cream alone
Number of subjects: 20
Study 15862200 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography (MEG) measuring gamma oscillations (30-70 Hz) in human visual cortex
Number of subjects: 0
Study 15862200 — intervention group
Group type: COMPARATOR
Intervention: Invasive measures of activation in primate visual cortex
Number of subjects: 0
Study 12075760 — intervention group
Group type: EXPERIMENTAL
Intervention: AZM 10 mg/kg/day
Number of subjects: 501
Study 12075760 — intervention group
Group type: EXPERIMENTAL
Intervention: AZM 20 mg/kg/day
Number of subjects: 501
Study 12075760 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 501
Study 9793623 — intervention group
Group type: COMPARATOR
Intervention: Klimonorm (Test preparation)
Number of subjects: 32
Study 9793623 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 32
Study 9793623 — intervention group
Group type: COMPARATOR
Intervention: Klimonorm (Test preparation) and Reference preparation
Number of subjects: 32
Study 7910865 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2231
Study 2941493 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha-2 interferon (rIFN-alpha 2) at a dosage of 2 X 10(6) units, administered three times per week for one year
Number of subjects: 0
Study 2941493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2941493 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha-2 interferon (rIFN-alpha 2)
Number of subjects: 0
Study 2941493 — intervention group
Group type: COMPARATOR
Intervention: Recombinant alpha-2 interferon (rIFN-alpha 2) and Placebo
Number of subjects: 0
Study 29843276 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted training using Armeo Spring
Number of subjects: 34
Study 29843276 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control Group)
Number of subjects: 34
Study 26638130 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g four times a day for 5 days
Number of subjects: 80
Study 26638130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26638130 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 80
Study 23886272 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) treatment in FM patients
Number of subjects: 0
Study 23886272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21481958 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.3 mg/kg/min, administered weekly for 6h over 6 months)
Number of subjects: 63
Study 21481958 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (10 mg/kg/min, administered weekly for 6h over 6 months)
Number of subjects: 63
Study 21481958 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (10 mg/kg/min) + Levosimendan (0.2 mg/kg/min, administered weekly for 6h over 6 months)
Number of subjects: 63
Study 21481958 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 63
Study 20670240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine stained with methylene blue
Number of subjects: 63
Study 17346378 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal construct psychotherapy
Number of subjects: 64
Study 17346378 — intervention group
Group type: COMPARATOR
Intervention: Normal clinical practice
Number of subjects: 64
Study 15764270 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessment using EORTC QLQ-C30 questionnaire
Number of subjects: 917
Study 15764270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and fatigue assessment
Number of subjects: 917
Study 15764270 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and disease-related factors analysis
Number of subjects: 917
Study 15764270 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of QOL scores
Number of subjects: 917
Study 12032012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis
Number of subjects: 26
Study 12032012 — intervention group
Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 26
Study 12032012 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 26
Study 9521970 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter followed by automated telephone message
Number of subjects: 648
Study 9521970 — intervention group
Group type: COMPARATOR
Intervention: Letter alone
Number of subjects: 648
Study 9521970 — intervention group
Group type: COMPARATOR
Intervention: Automated telephone message alone
Number of subjects: 648
Study 9521970 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone message followed by letter
Number of subjects: 648
Study 9521970 — intervention group
Group type: COMPARATOR
Intervention: No systematic intervention (comparison group)
Number of subjects: 648
Study 7743760 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 40
Study 7743760 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 40
Study 2404837 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to the other platinum compound (carboplatin if initially treated with cisplatin, and vice versa)
Number of subjects: 54
Study 2404837 — intervention group
Group type: COMPARATOR
Intervention: Rechallenged with the same drug (cisplatin or carboplatin)
Number of subjects: 54
Study 2404837 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (both crossover and rechallenged)
Number of subjects: 54
Study 2404837 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who relapsed before 18 months
Number of subjects: 54
Study 2404837 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who relapsed after 18 months
Number of subjects: 54
Study 7304657 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefaclor (2 g orally)
Number of subjects: 52
Study 7304657 — intervention group
Group type: COMPARATOR
Intervention: Multidose cefaclor (250 mg orally three times a day for 10 days)
Number of subjects: 52
Study 7304657 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefaclor (2 g orally) with ACB test (less inclusive criteria)
Number of subjects: 52
Study 7304657 — intervention group
Group type: COMPARATOR
Intervention: Multidose cefaclor (250 mg orally three times a day for 10 days) with ACB test (less inclusive criteria)
Number of subjects: 52
Study 7304657 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB test (less inclusive criteria)
Number of subjects: 52
Study 7304657 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB test (more inclusive criteria)
Number of subjects: 52
Study 7304657 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP test
Number of subjects: 52
Study 30445272 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT CARE intervention (provider capacity building, group sessions, individual sessions)
Number of subjects: 2448
Study 30445272 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard care)
Number of subjects: 2448
Study 30445272 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT CARE intervention (provider capacity building, individual sessions)
Number of subjects: 2448
Study 30445272 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT CARE intervention (individual sessions within first six months)
Number of subjects: 2448
Study 28780479 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) + docetaxel (D)
Number of subjects: 385
Study 28780479 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 385
Study 25496917 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day)
Number of subjects: 99
Study 25496917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 24041373 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized pesticide storage facility
Number of subjects: 4446
Study 24041373 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 4446
Study 21857013 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative visit by the same anaesthetist (Group 1)
Number of subjects: 3
Study 21857013 — intervention group
Group type: COMPARATOR
Intervention: Postoperative visit by a nurse anaesthetist (Group 2)
Number of subjects: 3
Study 21857013 — intervention group
Group type: COMPARATOR
Intervention: No visit (Group 3)
Number of subjects: 3
Study 20191714 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention during laceration repair
Number of subjects: 57
Study 20191714 — intervention group
Group type: EXPERIMENTAL
Intervention: Father present during procedure
Number of subjects: 57
Study 20191714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 57
Study 17223870 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl aminolaevulinate (MAL) cream (160 mg g(‐1)) applied for 3 hours
Number of subjects: 16
Study 17223870 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied for 3 hours
Number of subjects: 16
Study 15160686 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health intervention consisting of an evidence-based nursing protocol, patient self-care guide, and training to improve nurses' teaching and support skills
Number of subjects: 371
Study 15160686 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health intervention
Number of subjects: 371
Study 11282425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence bronchoscopy (LIFE group)
Number of subjects: 64
Study 11282425 — intervention group
Group type: COMPARATOR
Intervention: White light bronchoscopy (Control group)
Number of subjects: 64
Study 9621830 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior encoding of a word through visual perception (reading aloud)
Number of subjects: 0
Study 9621830 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior encoding of a word through a task providing no direct visual experience (generation from a semantic cue)
Number of subjects: 0
Study 9621830 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful identification of target words
Number of subjects: 0
Study 9621830 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective estimates of the proportion of targets previously studied
Number of subjects: 0
Study 7610529 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycyclin 2 x 100 mg p. o. for at least 14 days or Cefuroxim 2 x 500 mg if contraindicated
Number of subjects: 0
Study 7610529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxon 1 x 2‐‐2 x 2 g i. v. or Cefotaxim 3 x 2 g i. v. for at least 14 days
Number of subjects: 0
Study 7610529 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids in defined cases (pain syndrome)
Number of subjects: 0
Study 7610529 — intervention group
Group type: COMPARATOR
Intervention: Untreated patient groups
Number of subjects: 0
Study 2782043 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa 100 mg plus benserazide 25 mg
Number of subjects: 14
Study 2782043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 959118 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed influenza vaccine given by injection
Number of subjects: 0
Study 959118 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vaccination for high-risk groups (e.g., elderly, key workers)
Number of subjects: 0
Study 31308276 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 8% arginine and calcium carbonate (Group A)
Number of subjects: 40
Study 31308276 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm) irradiation (Group B)
Number of subjects: 40
Study 31308276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of dentifrice and diode laser (Group C)
Number of subjects: 40
Study 31308276 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (Group D)
Number of subjects: 40
Study 27868372 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg once daily
Number of subjects: 20
Study 27868372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26065919 — intervention group
Group type: EXPERIMENTAL
Intervention: P2-VP8 vaccine (10, 30, or 60 μg)
Number of subjects: 48
Study 26065919 — intervention group
Group type: EXPERIMENTAL
Intervention: P2-VP8 vaccine (60 μg)
Number of subjects: 48
Study 26065919 — intervention group
Group type: EXPERIMENTAL
Intervention: P2-VP8 vaccine (any dose)
Number of subjects: 48
Study 26065919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22924571 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (dose based on IGF-I titration algorithm; n = 114)
Number of subjects: 151
Study 22924571 — intervention group
Group type: COMPARATOR
Intervention: Observation (n = 37)
Number of subjects: 151
Study 21422084 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (0.75 g/kg)
Number of subjects: 80
Study 21422084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% glucose)
Number of subjects: 80